Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results August 2, 2022August 10, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche announces positive Phase III results for…European Commission approves Roche’s Tecentriq SC,…Positive topline phase III results show Roche's…New England Journal of Medicine publishes landmark…Roche announces positive data from global phase III…FDA grants priority review to Xolair (omalizumab)…
